Keensight Capital completed the acquisition of Inke from Neuraxpharm for $263m.

Keensight Capital, a growth buyout firm, completed the acquisition of Inke, a specialized inhalation active pharmaceutical ingredients developer and manufacturer, from Neuraxpharm, a specialty pharmaceutical company, for $263m. “This transaction is beneficial for all parties. Inke, its customers and employees will benefit from Keensight Capital’s expertise and investment track record in the healthcare sector. The new owner gets a highly differentiated specialist with a focus on micronized APIs for inhalation drugs, a high-growth segment of the market with strong entry barriers, while at Neuraxpharm we can continue to execute on our strategy of further solidifying our leading European market positioning in treating CNS disorders. We wish the whole Inke team all the best for this exciting new chapter of their success story,” Jörg-Thomas Dierks, Neuraxpharm CEO.